---
title: 'Factors associated with refractoriness or early progression after idecabtagene
  vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy
  Consortium real world experience'
date: '2023-10-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37855036/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20231020180754&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: While response rates and survival outcomes have been very promising for
  idecabtagene vicleucel (ide-cel), a proportion of patients do not respond or relapse
  early after this B-cell maturation antigen (BCMA) targeted CAR T-cell therapy. Understanding
  the characteristics of these patients is important for patient selection and development
  of novel strategies to improve outcomes. We evaluated factors associated with early
  progression (progression or death due to myeloma ≤ 3 months after CAR ...
disable_comments: true
---
While response rates and survival outcomes have been very promising for idecabtagene vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell maturation antigen (BCMA) targeted CAR T-cell therapy. Understanding the characteristics of these patients is important for patient selection and development of novel strategies to improve outcomes. We evaluated factors associated with early progression (progression or death due to myeloma ≤ 3 months after CAR ...